Dapiglutide - Zealand Pharma
Alternative Names: Dual GLP-1R/GLP-2R agonist - Zealand Pharma; Dual-acting peptide therapeutic - Zealand Pharma; Dual-GLP-1/GLP-2 acting peptide - Zealand Pharma; GLP-1/GLP-2 receptor agonist - Zealand Pharma; ZP-7570Latest Information Update: 10 Jan 2025
At a glance
- Originator Zealand Pharma
- Class Obesity therapies; Peptides
- Mechanism of Action Glucagon-like peptide 2 receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
- No development reported Gastrointestinal disorders; Short bowel syndrome
Most Recent Events
- 23 Dec 2024 Zealand Pharma initiates a phase I trial for Obesity in Germany (SC) (NCT06758583)
- 09 Sep 2024 Efficacy and adverse events data from the phase II trial in Obesity presented at 60th Annual Meeting of the European Association for the Study of Diabetes
- 09 Sep 2024 Efficacy, pharmacokinetics and adverse events data from a phase Ib trial in Obesity released by Zealand Pharma